Semaglutide vs Liraglutide
Both Semaglutide and Liraglutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Semaglutide
Evidence A+Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
View full Semaglutide profile →Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →Side-by-Side
| Attribute | Semaglutide | Liraglutide |
|---|---|---|
| Evidence Grade | A+ | A+ |
| FDA Status | FDA-approved for weight management and type 2 diabetes | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) |
| Typical Dose | 0.25–2.4 mg weekly (subcutaneous injection) | 0.6–3.0 mg daily (subcutaneous) |
| Clinics Indexed | 2,285 | 540 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Semaglutide
- ✓Significant weight loss
- ✓Appetite suppression
- ✓Blood sugar control
- ✓Cardiovascular benefit
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.